Transfusion-related acute lung injury
Description
- Non-cardiogenic pulmonary oedema within 6 hours of transfusion
- Acute hypoxaemia + bilateral infiltrates + no evidence of left atrial hypertension or circulatory overload
- Hypotension is characteristic (whereas TACO gives hypertension)
- Often with fever, rigors, transient leucopenia
- *The commonest cause of transfusion-related death before haemovigilance-driven donor deferral; still a leading cause*
Epidemiology
- ~1 in 5,000-10,000 units transfused; falling steeply since male-predominant plasma donor policies
- Plasma-rich components carry the highest risk: FFP is the most commonly implicated product, then apheresis platelets, then red cells
- No sex or age predilection in recipients
- Higher risk in critically ill, septic, post-cardiac-surgery, massive transfusion and haematological patients
Aetiopathogenesis
Two-hit model
- First hit (recipient) - a primed pulmonary endothelium and adherent neutrophils
- Sepsis, recent surgery (especially cardiac), trauma, mechanical ventilation, chronic alcohol use, shock, active malignancy
- Second hit (product) - one of:
- Immune (~80%): donor anti-HLA class I/II or anti-HNA (human neutrophil antigen) antibodies binding recipient leucocytes
- -> neutrophil activation, aggregation in pulmonary capillaries, oxidative burst, protease release
- -> capillary leak and protein-rich pulmonary oedema
- *Antibodies come from the donor, and are commonest in multiparous women* - hence the shift to male plasma
- Non-immune: biologically active lipids and CD40 ligand accumulating during component storage
- Immune (~80%): donor anti-HLA class I/II or anti-HNA (human neutrophil antigen) antibodies binding recipient leucocytes
- Rarely, recipient antibodies against donor leucocytes (reverse TRALI) - passenger leucocytes in the product
2019 consensus redefinition
- TRALI type I - no ARDS risk factors present
- TRALI type II - ARDS risk factors present, or existing mild ARDS that worsens
- "Possible TRALI" as a category has been retired
Diagnosis
*A clinical diagnosis of exclusion, made at the bedside.*
Criteria
- Onset within 6 hours of transfusion (usually 1-2 h)
- Acute hypoxaemia - PaO2/FiO2 <=300 mmHg, or SpO2 <90% on room air
- Bilateral pulmonary infiltrates on CXR
- No evidence of left atrial hypertension / circulatory overload as the sole explanation
- No pre-existing ARDS (type I) or ARDS risk factors present with worsening (type II)
Supporting features
- Hypotension (often the discriminating sign), fever, rigors
- Transient leucopenia and monocytopenia in the first hours - neutrophils sequestered in the lung
- Frothy, protein-rich pulmonary secretions
- Normal or low BNP; normal JVP; normal echo
The distinction that matters - TRALI vs TACO
| TRALI | TACO | |
|---|---|---|
| Blood pressure | Hypotension | Hypertension |
| JVP / fluid balance | Normal | Raised, positive balance |
| Fever | Common | Absent |
| WCC | Transient leucopenia | Normal |
| BNP/NT-proBNP | Normal | Raised |
| Echo | Normal LV | Elevated filling pressures |
| Pulmonary oedema fluid | Protein-rich (exudate) | Transudate |
| Response to diuretic | None - may harm | Rapid improvement |
| Risk group | Any; primed endothelium | Elderly, cardiac or renal failure, small body size, rapid/large volume |
Other differentials
- Anaphylactic transfusion reaction - earlier (minutes), urticaria, angioedema, bronchospasm
- Bacterial contamination/septic transfusion reaction - high fever, rigors, shock
- Aspiration, pneumonia, pulmonary embolism, transfusion-associated dyspnoea
Investigations
- ABG, CXR, BNP, echocardiogram, FBE (leucopenia)
- Notify the blood service - donor and recipient HLA/HNA antibody testing and cross-matching of donor antibody against recipient antigen
- Confirms the mechanism and, more importantly, allows the implicated donor to be deferred permanently**
Management
*Supportive only. There is no specific therapy.*
A. Immediate
- Stop the transfusion; keep IV access with saline
- Oxygen; escalate to high-flow, CPAP or intubation as required (~70-80% need ventilatory support, ~20-40% invasive ventilation)
- Lung-protective ventilation - low tidal volume (6 mL/kg predicted body weight), as for ARDS
- Fluid resuscitation and vasopressors for hypotension
B. What NOT to do
- *Diuretics do not help and can worsen hypotension* - the problem is capillary leak, not volume
- If the distinction from TACO is genuinely unclear, cautious diuresis with close monitoring is reasonable, but hypotension argues against it
- Corticosteroids have no proven benefit
- Do not give further plasma-rich components from the implicated donor
C. Reporting and prevention
- Report every case to the blood service and the haemovigilance programme - this is what drives donor deferral and has reduced incidence
- Implicated donors are permanently deferred from plasma and platelet donation
D. Systemic prevention (already in place in Australia)
- Male-predominant (or previously untransfused, nulliparous female) plasma for FFP
- Female apheresis platelet donors with a pregnancy history screened for HLA antibodies
- Universal leucodepletion
- *And the single most effective measure: avoid unnecessary transfusion* - particularly prophylactic FFP for mildly abnormal clotting in non-bleeding patients
E. Future transfusion
- The recipient is NOT at increased risk of recurrence (the antibody was the donor's)
- No special products required subsequently - unlike most other transfusion reactions
Associations
- Fresh frozen plasma and apheresis platelets (plasma-rich components)
- Multiparous donors - anti-HLA/anti-HNA antibodies from prior pregnancy
- Recipient priming states - sepsis, cardiac surgery, massive transfusion, chronic alcohol excess, shock, mechanical ventilation, haematological malignancy
- ARDS (shares the final common pathway)
- TACO (the principal differential, and they can coexist)
- Transfusion-associated dyspnoea, anaphylactic and septic transfusion reactions
- IVIG and other plasma-derived products (rare reports)
Natural history & complications
- *Usually resolves within 48-96 hours* - much faster than ARDS from other causes
- CXR clears within days; most survivors have no long-term respiratory sequelae
- Mortality ~5-10% (higher in critically ill and haematology patients)
- A minority progress to established ARDS with prolonged ventilation
Complications
- Respiratory failure requiring intubation and prolonged ICU stay
- Ventilator-associated pneumonia, barotrauma
- Multi-organ failure in the already critically ill
- Under-recognition - frequently misattributed to TACO, pneumonia or the underlying illness, so the donor is never identified and continues to donate
🔒
6 more sections, plus exam facts
Premium unlocks every note across every specialty, and the full exam fact library behind it.
Get premium access